Assessing Efferocytosis in Atherosclerotic Lesions In Situ.
Assessing Efferocytosis in Atherosclerotic Lesions In Situ.
复制标题
评估原位动脉粥样硬化病变中的胞吞作用。
DOI：
10.1007/978-1-0716-1924-7_34
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
YurdagulJr,Arif
中科院分区：
文献类型：
--
作者：
YurdagulJr,Arif
虽然大多数动脉粥样硬化病变是相对良性的，但一些具有大坏死核心和薄纤维帽的斑块容易破裂，从而导致许多心血管事件和猝死。凋亡细胞清除的缺陷，称为“efferocytosis”，是坏死核心扩张的主要原因。本章描述了一种在动脉粥样硬化病变中识别巨噬细胞相关的末端脱氧核苷酸转移酶（TUNEL）阳性事件（即efferocytosis事件）和与巨噬细胞无关的TUNEL事件（即未清除的凋亡事件）的方法。这项检测对于了解临床上危险的动脉粥样硬化斑块是如何形成的至关重要，并将继续是一项重要的检测，揭示巨噬细胞如何进行efferocytosis以及随着动脉粥样硬化的进展，这一过程如何变得有缺陷。
Whereas most atherosclerotic lesions are relatively benign, some plaques with large necrotic cores and thin fibrous caps are vulnerable to rupture, which results in many cardiovascular events and sudden death. Defects in the clearance of apoptotic cells, termed “efferocytosis,” is the leading cause of necrotic core expansion. This chapter describes a method that identifies macrophage-associated terminal deoxynucleotidyl transferase (TUNEL)-positive events (i.e., efferocytosis events) and TUNEL events free from association with macrophages (i.e., uncleared apoptotic events) in atherosclerotic lesions. This assay has been critical to the understanding of how clinically dangerous atherosclerotic plaques form and will remain a crucial assay that reveals new insights into how macrophages carry out efferocytosis and how this process becomes defective as atherosclerosis advances.